Dermatologic Inflammation in vivo modeling
CBI provides a range of acute, chronic and immune-mediated dermal pharmacology models. Acute or chronic inflammation is induced and the ability of the test article to suppress the inflammation is determined.
Local Irritation and Tolerability
To determine if a test article is a local irritant, it is applied topically to intact or abraded skin, with or without coverage. The site is scored using a Draize-type score.
In these models, uniform wounds or dermal burns are created surgically and healing assessed. Typical wounds would include full thickness, split thickness and single cuts. Typical burns would include full and partial thickness burns. The test article is administered and the effects of the test article on the rate and character of healing are determined. Thermal and UVB light-induced models of dermal burns are also offered.
Test articles may be assessed for their abilities to reduce inflammation or conversely to determine if they themselves act as sensitizers. In this model, DTH is induced with the established sensitizers, oxalazone or TNBF. There are minimally two inductions followed by a challenge and treatment with the test article.
- Oxalazone-induced DTH
- TNBF-induced DTH
GP sensitization or maximization assays determine if test articles themselves are sensitizers. The test article is applied topically during induction, followed by challenge. Application sites are scored using Draize’s test. Typically, there is a vehicle, two to three dose levels of test article and a positive control sensitizer. Types of methods include:
- Beuhler method
- Magnusson-Kligman method
Drug Delivery Devices Used on the Skin
There are many new experimental methods and devices used to deliver a test article to the skin for either local or systemic absorption. The effects of these devices on the skin as well as the ability of the device to deliver the test article may be determined.